Affordable Access

deepdyve-link
Publisher Website

Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.

Authors
  • Tamari, Roni
  • Castro-Malaspina, Hugo
Type
Published Article
Journal
Current Opinion in Hematology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Mar 01, 2015
Volume
22
Issue
2
Pages
184–190
Identifiers
DOI: 10.1097/MOH.0000000000000121
PMID: 25635756
Source
Medline
License
Unknown

Abstract

Improvements in the field of allo-HSCT, the ability to improve patient's performance status prior to transplant with JAK1/2 inhibitors and a more accurate disease risk stratification based on molecular mutations to select patients who can benefit from allo-HSCT should result in better transplant outcomes. Efforts should be made to transplant patients with myelofibrosis on prospective studies to answer some unresolved questions.

Report this publication

Statistics

Seen <100 times